Xiangxue Pharmaceutical Co.,Ltd. (SHE:300147)
China flag China · Delayed Price · Currency is CNY
6.28
+0.03 (0.48%)
Sep 2, 2026, 3:04 PM CST

Xiangxue Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
-1,426-1,392-858.56-388.96-530.06-688.47
Depreciation & Amortization
182.29193.94226.42237.3239.39149.91
Other Amortization
9.127.4316.758.047.6914.98
Loss (Gain) From Sale of Assets
-7.84-8.92-6.990.09-4.88-2.34
Asset Writedown & Restructuring Costs
539.73556.49334.92105.38129.73444.56
Loss (Gain) From Sale of Investments
3.251.614.8960.01-47.32-49.23
Other Operating Activities
315.68318.5275.44270.71249.13269.71
Change in Accounts Receivable
101.9940.61-54.7462.89-106.33-14.75
Change in Inventory
-12.7632.39-7.279.6218.6542.85
Change in Accounts Payable
342.98348.6952.61-126.51266.2886.44
Change in Other Net Operating Assets
38.7932.2933.0217.1121.76-1.66
Operating Cash Flow
98.15139.6318.17263.44227.38257.56
Operating Cash Flow Growth
-668.28%-93.10%15.86%-11.72%0.15%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-27.68-21.51-35.24-56.03-367.27-562.74
Sale of Property, Plant & Equipment
5.115.0130.41-24.710.17
Cash Acquisitions
------154.32
Divestitures
--41.260.36435.7459.35
Investment in Securities
6.393.9623.411.5326.42864.36
Other Investing Activities
-0.96--24.870.48259.67-319.63
Investing Cash Flow
-17.15-12.5434.96-53.66379.26-112.8

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Short-Term Debt Issued
-----206.36
Long-Term Debt Issued
-125.98224.48379.481,1514,406
Total Debt Issued
160.58125.98224.48379.481,1514,612
Long-Term Debt Repaid
--102.68-206.62-429.19-1,468-4,881
Total Debt Repaid
-126.62-102.68-206.62-429.19-1,468-4,881
Net Debt Issued (Repaid)
33.9723.317.86-49.71-316.96-269.06
Repurchase of Common Stock
-----0.27-0.38
Common Dividends Paid
-2.76-5.84-50.55-140.66-175.8-216.91
Other Financing Activities
-31.88-19.59-35.26-10.26-159.7436.13
Financing Cash Flow
-0.67-2.13-67.95-200.63-652.77-450.22

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Foreign Exchange Rate Adjustments
-0.08-0.020-00.9-0.09
Net Cash Flow
80.24124.94-14.819.15-45.23-305.56

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
70.46118.12-17.07207.41-139.89-305.18
Free Cash Flow Growth
------
Free Cash Flow Margin
4.76%7.40%-0.92%9.02%-6.40%-10.27%
Free Cash Flow Per Share
0.110.18-0.030.32-0.21-0.46
Levered Free Cash Flow
1,5391,474554.1616.2928.8352.33
Unlevered Free Cash Flow
1,7171,652699.69164.46162.08178.62

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
54.9859.1895.7272.1365.98116.17
Change in Working Capital
482.13462.7625.31-29.13183.69118.44